Free Trial

HLS Therapeutics Q2 2024 Earnings Report

HLS Therapeutics logo
C$3.99 -0.05 (-1.24%)
As of 03/10/2025 03:10 PM Eastern

HLS Therapeutics EPS Results

Actual EPS
-C$0.25
Consensus EPS
-C$0.25
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

HLS Therapeutics Revenue Results

Actual Revenue
$19.87 million
Expected Revenue
$19.25 million
Beat/Miss
Beat by +$620.00 thousand
YoY Revenue Growth
N/A

HLS Therapeutics Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Remove Ads

HLS Therapeutics Earnings Headlines

Top Canadian Pharmaceutical Stocks of 2025
Optimistic Buy Rating for HLS Therapeutics Despite Revenue Challenges
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
See More HLS Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HLS Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HLS Therapeutics and other key companies, straight to your email.

About HLS Therapeutics

HLS Therapeutics (TSE:HLS) Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States and the Rest of the world.

View HLS Therapeutics Profile

More Earnings Resources from MarketBeat